medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (4)

Autologous stem cell transplantation in monoclonal gammopathies: first results from the “Hermanos Ameijeiras” Hospital

Hernández CC, Carnot UJ, de la Campa JD, Muñío PJ, Pardo RIK, García GA, Ríos JO, Rodríguez FY, Cepero LK

Language: Spanish
References: 17
Page: 1-11
PDF size: 757.00 Kb.


ABSTRACT

Introduction: The recent advances in the management of multiple myeloma (MM) during the last years have included the autologous hematopoietic stem cell transplantation (auto-HSCT) to the treatment strategy of these patients. Objective: To present the first results in the "Hermanos Ameijeiras" hospital (HAH) with the application of auto-HSCT in patients with monoclonal gammopathies (MG) using high doses of melphalan (HD-Mel) as conditioning regimen (CR) and its impacton overall survival (OS). Methods: A retrospective study of all patients with MG who underwent auto-HSCT in the Hematology Service of the HAH in the period between 2009 and 2018 wasmade. The final sample comprised 14 cases. Results: The average age was 53.5 years; the majority had diagnosis of MM (85.7%) and all of them were diagnosed in stage III of Durie-Salmon; as CR 64.2% received HD-mel, at 200 mg/m2. The recovery of neutrophil and platelet counts occurred on average at 11.4 and 12 days respectively. Transplant related mortality (TRM) at day +30 was 7.1%. The probability of OS at 2 years was higher than 90% and at 5 years of 68%. Conclusions: It was verified that the performance of auto-HSCT with the use of HD-Mel as CR in patients with MG is a feasible procedure in our country with a relatively low TRM. It was possible to demonstrate that the inclusion of auto-HSCT in the treatment considerably improves the survival expectations of these patients.


REFERENCES

  1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-8.

  2. Bladé J, Vesole DH, GertzM. High-dose therapy in multiple myeloma. Blood 2003;102(10):3469-70.

  3. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol 2018;93(8):981-1114.

  4. D’Souza A, Fretham C. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2018. (citado: 17/05/2019) Available at: https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/_layouts/15/WopiFrame.aspx?sourcedoc=/ReferenceCenter/SlidesReports/SummarySlides/Documents/2018%20Summary%20Slides%20-%20final%20-%20for%20web%20posting.pptx&action=default

  5. Cuba. Registro Nacional de Cáncer de Cuba[Internet].2011[citado 17/05/2019]. Disponible en:http://www.rnc.sld.cu/wp-content/uploads/2013/10/Incidencia-de-c%C3%A1ncer-seg%C3%BAn-sexo-y-localizaci%C3%B3n_CUB-A-2011.pdf

  6. Cuba. Registro Nacional de Cáncer de Cuba[Internet].2012[citado 17/05/2019]. Disponible en: http://www.rnc.sld.cu/wp-content/uploads/2013/10/Incidencia-de-c%C3%A1ncer-seg%C3%BAn-sexo-y-localizaci%C3%B3n_Cub-a_2012.pdf

  7. Cuba. Registro Nacional de Cáncer de Cuba[Internet].2013[citado 17/05/2019]. Disponible en:http://www.rnc.sld.cu/wp-content/uploads/2013/10/a%C3%B1o-2013-CUBA-nuevo.pdf

  8. Cuba. Registro Nacional de Cáncer de Cuba[Internet].2014[citado 17/05/2019]. Disponible en:http://www.rnc.sld.cu/wp-content/uploads/2016/07/Incidencia-de-C%C3%A1ncer-en-Cuba-2014.pdf

  9. Ruiz-Argüelles GJ, Lobato-Mendizábal E, Ruiz-Argüelles A, Pérez-Romano B, Arizpe-Bravo D, Marín-López A. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long term results. Arch Med Res 1999;30(5):380-4.

  10. Kumar S, Paiva B, Anderson KC, Durie B,LandgrenO,Moreau P, et al. International MyelomaWorking Group consensus criteria for response and minimal residual disease assessment inmultiple myeloma. Lancet Oncol 2016;17(8):328-46.

  11. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc.1958;53:457.

  12. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al.Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371(10):895-905.

  13. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104(10):3052-7.

  14. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomized, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617-29.

  15. Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J et al. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019;19(6):332-44.

  16. Kumar SK, Buadi FK, Rajkumar SV. Pros and cons of front line autologous transplant in multiple myeloma: the debate over timing. Blood 2019;133:652-9.

  17. Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple mieloma. Blood Cancer J 2019; 9(4):44.




2020     |     www.medigraphic.com